Affordable Growth. Analyze the stocks which are showing good growth, decent profitability and health and are not overvalued from a fundamental perspective.
Overall HALO gets a fundamental rating of 8 out of 10. We evaluated HALO against 562 industry peers in the Biotechnology industry. HALO gets an excellent profitability rating and is at the same time showing great financial health properties. HALO is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, HALO could be worth investigating further for value and growth and quality investing!.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 22.1% | ||
ROE | 100.64% | ||
ROIC | 23.44% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 55.1% | ||
PM (TTM) | 44.76% | ||
GM | 83.45% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 3.13 | ||
Debt/FCF | 3.04 | ||
Altman-Z | 5.18 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.39 | ||
Quick Ratio | 7.3 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 11.55 | ||
Fwd PE | 7.71 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 13.09 | ||
EV/EBITDA | 12.39 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |